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Neuroinflammation is an important contributor to neuronal pathol-
ogy and death in neurodegenerative diseases and neuronal injury.
Therapeutic interventions blocking the activity of the inflammatory
kinase IKKβ, a key regulator of neuroinflammatory pathways, is
protective in several animal models of neurodegenerative disease
and neuronal injury. In Huntington’s disease (HD), however, signif-
icant questions exist as to the impact of blocking or diminishing the
activity of IKKβ on HD pathology given its potential role in Hunting-
tin (HTT) degradation. In cell culture, IKKβ phosphorylates HTT ser-
ine (S) 13 and activates HTT degradation, a process that becomes
impaired with polyQ expansion. To investigate the in vivo relation-
ship of IKKβ to HTT S13 phosphorylation and HD progression, we
crossed conditional tamoxifen-inducible IKKβ knockout mice with
R6/1 HD mice. Behavioral assays in these mice showed a significant
worsening of HD pathological phenotypes. The increased behavior-
al pathology correlated with reduced levels of endogenous mouse
full-length phospho-S13 HTT, supporting the importance of IKKβ in
the phosphorylation of HTT S13 in vivo. Notably, many striatal auto-
phagy genes were up-regulated in HD vs. control mice; however,
IKKβ knockout partially reduced this up-regulation in HD, increased
striatal neurodegeneration, and enhanced an activated microglial
response. We propose that IKKβ is protective in striatal neurons
early in HD progression via phosphorylation of HTT S13. As IKKβ
is also required for up-regulation of some autophagy genes and HTT
is a scaffold for selective autophagy, IKKβmay influence autophagy
through multiple mechanisms to maintain healthy striatal function,
thereby reducing neuronal degeneration to slow HD onset.
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The development of effective treatments for neurodegenera-tive diseases critically depends on an understanding of the
sources of pathology. In Huntington’s disease (HD), the genetically
based primary cause of pathology is expansion of a CAG repeat
encoding polyglutamine (polyQ) within the huntingtin (HTT)
protein (1). While the physical properties of the polyQ repeat are a
key element in HD pathology, polyQ expansion can also have an
important impact on the functional properties of HTT itself.
We previously found that phosphorylation of HTT at serines
(S) 13 and 16 can activate HTT clearance in cells (2), reduce
aggregate accumulation and block HD progression in HD mice
(3). This phosphorylation is impaired by polyQ expansion (2),
suggesting that this posttranslational modification may be critical
to HD pathogenesis. We further showed that the inflammatory IκB
kinase complex (IKK) activates phosphorylation of HTT S13 and
S16 and enhances HTT clearance (2). IKK is a cytokine-induced
serine kinase that controls the activation of NF-κB, a ubiquitous
transcription factor closely associated with inflammation (4). While
inflammation has been implicated in neurodestructive outcomes in
late stages of HD, Alzheimer’s disease (AD), and Parkinson’s
disease (PD), immunoactivities and inflammatory processes may
also be neuroprotective early in disease progression (5, 6). IKK is
activated by acute cellular stress and has previously been shown to
contribute to the induction of autophagy (7–9). To prevent
continuous activation of IKK, autophagic degradation of IKK
itself occurs through a negative feedback loop (10, 11). As
autophagy declines with aging (12), an accumulation of IKK
over time can cause its excessive activation and harmful re-
sponses such as tumorigenesis and inflammation (13).
IKK induces expression of several autophagy-related genes
independent of its activation of NF-κB and has been proposed to
play a more direct role in autophagy regulation through the
phosphorylation of autophagy proteins (8, 9). The IKK kinase
complex is composed of three subunits, α, β, and γ; α and β are
homologous catalytic subunits and γ is a regulatory subunit. IKKα
and IKKβ can directly phosphorylate HTT S13 and activate
phosphorylation of S16 (2). In turn, phosphorylation at these
residues increases HTT clearance in cells by the proteasome and
lysosome and reduces mutant HTT exon 1 protein-mediated cel-
lular toxicity (2). Extending these studies, we showed that mim-
icking S13 and S16 phosphorylation (S13,16D) in the context of
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full-length mutant HTT expression in vivo in BACHD mice com-
pletely blocked HD progression and aggregate formation (3),
supporting a possible direct association between phosphorylation
of HTT and mutant HTT clearance. IKK is activated in cell culture
and mouse models of HD chronically expressing mutant HTT (14),
potentially reflecting an initial compensatory effect that may help
phosphorylate HTT. These data are consistent with the innate
immune activation that is observed in presymptomatic HD patients
at least a decade before overt neurological manifestation of disease
(15). Over time, IKK activation and HTT phosphorylation would
be predicted to be less efficient in inducing HTT degradation be-
cause of reduced function of the proteasome and lysosome with
aging (16) and might contribute to the chronic inflammation as-
sociated with neuronal cell death paralleling other hallmarks of
HD pathogenesis (2, 5, 6).
In this work we tested the relationship of IKKβ to HD path-
ogenesis. We determined that HD behavioral phenotypes are
further impaired in R6/1 HD mice upon IKKβ knockout, par-
alleling striatal neurodegeneration and an activated microglial
response. We found that the kinase IKKβ is responsible in vivo
for phosphorylation of HTT S13, the regulation of striatal WT
full-length HTT abundance in nontransgenic (NT) control and
R6/1 (HD) mice, and the activation of transcription of several
autophagy genes, potentially linking inflammatory signal trans-
duction pathways to the induction of HTT’s autophagic scaffold
function and autophagy in general. Thus, we find that IKKβ is
required in vivo to slow the early stages of HD progression in R6/
1 mice and suggest that the impact of IKKβ expression early in
HD disease progression is due to IKKβ in vivo phosphorylation
of HTT S13 and to the effect of IKKβ expression on autophagy.
Results
Generation of R6/1 HD Mice with Conditional Tamoxifen-Inducible
IKKβ Knockout. The R6/1 mouse line is a widely employed HD
model that expresses a mutant human HTT exon 1 transgene
(17) and demonstrates a progressive decline in motor abilities
and cognitive and social behaviors starting around 12 to 14 wk of
age (18–21) accompanied by striatal atrophy and ventricular
enlargement (17, 18, 22). To investigate the in vivo relationship
of IKKβ to HTT S13 phosphorylation and HD progression, we
created conditional tamoxifen-inducible IKKβ knockout mice.
Transgenic mice with loxP-flanked alleles of IKKβ were crossed
with mice expressing the tamoxifen-inducible Cre recombinase
under control of the Wfs1, the Wolfram syndrome 1 homolog
(human) promoter/enhancer regions (23, 24). Wfs1 promotes
expression in neurons and astrocytes in several brain regions (25,
26). Efficient conditional IKKβ knockout was achieved in adult
tissue including striatum and liver, which were evaluated at the
completion of the study at 16 wk of age. Cre+, loxP-flanked al-
leles of IKKβ mice were crossed with R6/1 HD mice and IKKβ
knockdown was induced with tamoxifen vs. vehicle (oil) admin-
istered at week 10, at a time that mice do not have demonstrable
phenotypes, in R6/1 (HD) vs. NT WT controls. In this study, 9/
10 of the female NT mice did not survive 1 wk past tamoxifen
injection, and therefore only male mice were used for this work
(Tamoxifen Protocol).
IKKβ Knockout Exacerbates Behavioral Phenotypes in the R6/1 Mouse
Model of HD.R6/1 mice begin losing weight and show a decline in
behavioral tests beginning between 12 and 14 wk (20, 21), and
our results are consistent with those findings. No treatment ef-
fect on weight or grip strength was observed for tamoxifen-
induced IKKβ knockout in either R6/1 (HD) mice or NT WT
controls (SI Appendix, Fig. S1 A and B), and tamoxifen-induced
IKKβ knockout did not affect pole test or rotarod performance
in the NT controls (Fig. 1). Behavioral assessments demon-
strated significantly impaired pole test descending times (60%
slower) following tamoxifen-induced IKKβ knockout in HD mice
at 12 wk of age compared with oil-treated HD controls (Fig. 1A).
However, the increase in impairment was not significant at the
16-wk time point. HD mice with tamoxifen-induced IKKβ
knockout exhibited significantly impaired time (27% and 23%
less time) on rotating rod before fall compared with oil-treated
HD controls on weeks 13 and 15, respectively (Fig. 1B). The
impairment of rotarod and pole test tasks was not due to a
toxicity of tamoxifen treatment independent of IKKβ knockout,
as a separate cohort of tamoxifen-treated standard R6/1 HD
mice, without the Cre or floxed alleles of IKKβ, did not dem-
onstrate further impairment in these pole test or rotarod tasks
(SI Appendix, Fig. S2). Taken together, these results demonstrate
that tamoxifen-induced IKKβ knockout exacerbates neurological
phenotypes of R6/1 HD mice beyond the effect of mHTT
transgene expression alone. There were no significant differ-
ences across the battery of behavior assessments with IKKβ
knockout in NT control mice, supporting a selective role for
IKKβ in the disease setting.
IKKβ Is Required for Phosphorylation of HTT S13 in Vivo. We hy-
pothesized that the increased pathology observed in the IKKβ
knockout HD mice may be the consequence of failure of HTT
phosphorylation at amino acid S13 in this setting. We had pre-
viously found that IKKβ can directly phosphorylate HTT S13
using in vitro kinase assays, and that HTT S13 phosphorylation is
increased with overexpression of IKKβ or induction of IKKβ with
TNF-α or IL-1β treatment in cell culture, corresponding to an
activation of HTT clearance (2). We now designed studies to
evaluate whether IKKβ is a relevant HTT S13 kinase in vivo and
whether it regulates HTT levels. After behavioral testing ending
at week 16, IKKβ knockout and control mice were killed, and
liver and striatal tissue were collected for Western analysis to
measure levels of IKKβ, S13 phosphorylated full-length HTT,
total full-length HTT, and transgenic mutant HTT exon 1 pro-
tein. S13 phosphorylation is quantitated using an immunopre-
cipitation (IP) method that does not show nonspecific binding of
HTT to the IP beads (Materials and Methods), and total full-
length HTT and transgenic mutant HTT exon 1 protein are
each quantitated using whole-cell lysates. We evaluated protein
levels in striatum of tamoxifen- vs. oil-treated NT control and
HD mice, all expressing the tamoxifen-inducible Cre with the
floxed alleles of IKKβ. Consistent with the hypothesis that re-
duced IKKβ levels impacted the phosphorylation at S13 and
degradation of full-length HTT, tamoxifen treatment signifi-
cantly reduced IKKβ and increased levels of full-length HTT in
whole striatal cell extract and reduced relative levels of immu-
noprecipitated full-length S13 phosphorylated HTT in both NT
and HD striatum (Fig. 2).
Liver dysfunction has been observed in manifest and pre-
manifest HD patients and in HD mouse models (27, 28); we
therefore chose to also examine IKKβ knockout liver tissue in
our HD and NT control mice. Similar to striatum, IKKβ was
significantly reduced in liver homogenates from these animals
following tamoxifen treatment in both HD and NT control liver,
which tracked with reduced relative levels of S13 phosphorylated
HTT (Fig. 3), demonstrating the involvement of IKKβ in the
phosphorylation of HTT S13 in liver in vivo. However, levels of
full-length mouse HTT were not significantly altered in liver with
IKKβ knockout, unlike the significant increase in total full-length
HTT we observed in the striatum of the IKKβ knockout mice.
In both striatum and in liver, levels of transgenic mutant HTT
exon 1 protein were evaluated using immunofluorescence anal-
ysis to determine numbers of HTT aggregates and by Western
analysis to specifically detect human mutant HTT exon 1 protein
high-molecular-weight species with anti-HTT MAB5492, which
does not detect endogenous full-length mouse HTT. No significant
changes in HTT aggregate numbers or transgenic human mutant
HTT exon 1 protein levels were observed with IKKβ knockout in
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either striatum or liver (SI Appendix, Fig. S3). We did observe an
accumulation of lipid droplets in HD liver with IKKβ knockout
and higher liver IKKβ protein levels in oil-treated HD vs. NT
controls (SI Appendix, Fig. S4) consistent with increased liver
stress in R6/1 induced by expression of transgenic human mu-
tant HTT exon 1 protein.
We find that in both striatum and liver, knockout of IKKβ
reduces levels of S13-phosphorylated full-length HTT in NT and
HD mice, demonstrating IKKβ is a relevant kinase for HTT
S13 in vivo, but that levels of transgenic mutant HTT exon
1 protein and aggregate numbers were unaffected by IKKβ
knockout in striatum and liver. This is consistent with our pre-
vious findings that IKKβ does not efficiently phosphorylate
mutant HTT exon 1 protein with expanded polyglutamine re-
peats in cell culture (2). Liver IKKβ knockout (Fig. 3) was much
more extensive than that in striatum (Fig. 2). TheWfs1 promoter
we used to drive the tamoxifen-inducible Cre expression needed
for IKKβ knockout expresses well in medium spiny neurons and
astrocytes of the striatum, but not in microglia (SI Appendix, Fig.
S5A) (29). The residual levels of IKKβ detected by Western
analysis in striatum in tamoxifen-treated mice may reflect IKKβ
expression in microglia and may explain why the IKKβ knockout
was less efficient in striatum than in liver. Using qPCR analysis,
we did not observe any great alteration in levels of IKKβ ex-
pression in cortex or cerebellum with tamoxifen treatment, so
these tissues were not further examined (SI Appendix, Fig. S5B).
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Fig. 1. Effects of IKKβ knockout on behavior in male
R6/1 mice. Pole test (8, 12, and 16 wk) and rotarod (8,
13, and 15 wk) are shown for tamoxifen (TAM)- vs.
oil-treated R6/1 (HD) and NT controls (n = NT-Oil, 12;
NT-TAM, 12; HD-Oil, 9; HD-TAM, 12 at week 8, and
NT-Oil, 12; NT-TAM, 11; HD-Oil: 9, HD-TAM, 10 fol-
lowing injections). HD mice performed significantly
worse on 12-wk pole test (A) and on weeks 13 and
15 rotarod (B) with TAM-induced IKKβ knockout
than oil-treated HD control mice. No significant ef-
fect was observed in NT control mice with TAM-
induced IKKβ knockout. *P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001 values represent
means ± SEM. Statistical significance was determined
by one-way ANOVA with Bonferroni posttesting.
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Fig. 2. Levels of S13-phosphorylated HTT are re-
duced while total full-length (∼350 kDa) mouse HTT
abundance is increased with IKKβ knockout in stria-
tum, demonstrating that IKKβ is a relevant striatal
HTT S13 kinase in vivo. Male R6/1 (HD) and NT WT
controls, both containing the tamoxifen-inducible
Cre and floxed alleles of IKKβ, were treated with
tamoxifen or oil vehicle control during week 10 and
killed at week 16. IKKβ normalized to loading control
α-tubulin was significantly reduced in 16-wk striatum
of HD and NT mice with tamoxifen treatment over
oil control in whole-cell lysate (A–C ). Anti-HTT
phosphoserine 13 (pS13) antibody was used to im-
munoprecipitate phosphorylated full-length mouse
HTT which was then detected by Western blot with
anti-total HTT antibody. Levels of pS13-HTT were
significantly reduced relative to total HTT with IKKβ
knockout in HD and NT controls, while levels of total
HTT normalized to α-tubulin were significantly in-
creased (A–C). Western images (A and B) were
quantitated using Scion software (C). *P < 0.05,
**P < 0.01, ***P < 0.001, ****P < 0.0001 values
represent means ± SEM. Statistical significance was
determined by paired t test.
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IKKβ Regulates Expression of Autophagy-Related Genes in Vivo. A
link has been found between the activation of the IKK complex
and the induction of autophagy by an NF-κB–independent
mechanism, which may at least partially be the result of increased
autophagy gene expression (7, 8). To determine whether IKKβ
knockout in male striatum and liver might modulate expression of
autophagy genes in HD vs. NT control mice, we selected 20 genes
encoding proteins with known autophagy functions, in addition to
IKKβ itself, to evaluate by qRT-PCR analysis using RNA pre-
pared from frozen striatal and liver tissue collected at the end of
the study at week 16 (SI Appendix, Fig. S6).
In striatum, we observed a significant increase in expression of
13 out of 20 tested autophagy genes in HD vs. NT controls,
showing that expression of transgenic human mutant HTT exon
1 protein independent of IKKβ knockout may globally increase
striatal autophagy gene expression (SI Appendix, Fig. S7), con-
sistent with previously published RNA-sequencing data showing
up-regulated transcription of HTT, Atg14, Atg7, and p62 in R6/
1 vs. NT control mice (30). Of the 13 up-regulated autophagy
genes, 2 were significantly reduced in HD striatum with tamoxifen-
induced IKKβ knockout, Atg14 and GABARAPL1, suggesting
IKKβ expression may activate transcription of these autophagy
genes in HD striatum.
In contrast with striatum, we did not observe the global up-
regulation of autophagy genes in oil-treated HD vs. NT liver tissue
independent of tamoxifen-induced IKKβ knockout. In fact, we saw
a significant down-regulation of mAtg13, LC3A, LAMP-2A, and
LAMP-2C in oil-treated HD liver vs. oil-treated NT control liver.
Tamoxifen-induced IKKβ knockout significantly reduced expres-
sion of several liver autophagy genes in both HD and NT controls
(SI Appendix, Fig. S7B): HTT, Atg14, GABARAPL1, Atg16L,
Atg9A, and TFEB were significantly down-regulated in HD IKKβ
knockout liver, and HTT, mAtg13, Atg14, LC3A, GABARAPL1,
p62, and LAMP-2A were significantly down-regulated in NT
IKKβ knockout liver. This transcriptional analysis may suggest
that IKKβ has a greater impact on the basal expression of auto-
phagy genes in liver (independent of mutant HTT exon 1 protein
expression), whereas in striatum IKKβ knockout diminishes the
stress-induced up-regulation of Atg14 and GABARAPL1 caused
by mutant HTT exon 1 protein expression but has no effect on
basal autophagy gene expression in NT controls.
IKKβ Knockout and Mutant HTT Exon 1 Protein Expression Impact
Levels of Autophagy Proteins in Vivo. Mutant HTT exon 1 protein
expression can cause a compensatory activation of autophagy in
vivo but can also ultimately block autophagy, resulting in accu-
mulation of several autophagy proteins and autophagic cargo (31–
34). In striatum, expression of mutant HTT exon 1 protein results
in increased levels of the LC3 protein, a mammalian Atg8 whose
lipidation or accumulation is commonly assayed as an indicator of
autophagic flux (31, 35). We examined levels of LC3 protein in 16-
wk striatal and liver soluble fractions (Fig. 4) and only detected
unlipidated LC3 I by Western analysis in striatum, while detecting
both LC3 I and lipidated LC3 II in liver, similar to others who
have examined LC3 in brain vs. liver soluble fractions (35). In R6/
1 HD striatum, with or without IKKβ knockout, LC3 I protein
accumulates in the soluble fraction, suggestive of a blockage of
autophagic flux, while in liver no differences are observed in LC3 I
or II, suggestive of functional basal autophagy. Interestingly, we
saw a significant increase in striatal LC3 I levels in NT controls
with IKKβ knockout, demonstrating that a loss of IKKβ activity in
striatum may block autophagic flux independent of mutant HTT
exon 1 protein expression. We conclude that mutant HTT exon
1 protein and IKKβ knockout may both independently contribute
to LC3-dependent autophagy blockage in striatum. At 16 wk,
levels of LC3 I were high in HD striatum, and IKKβ knockout did
not further increase these levels; similarly, as mutant HTT exon
1 protein is cleared by autophagy, this may suggest why IKKβ
knockout did not further alter levels of aggregates in HD striatum
(SI Appendix, Fig. S3A). In liver tissue, LC3 I and II proteins were
detected and were unchanged with IKKβ knockout or with mutant
HTT exon 1 protein expression (Fig. 4), consistent with active
autophagic clearance of mutant HTT exon 1 protein reflected by
low levels of aggregates (SI Appendix, Fig. S3B), highlighting a
difference in autophagy between striatum and liver. We previously
found in cell culture that lysosomal membrane protein LAMP-2A
overexpression could reduce levels of HTT exon 1 protein (2). We
therefore examined levels of LAMP-2A protein, which were un-
changed at 16 wk in striatum but were significantly increased in
HD vs. NT controls in liver. This may suggest that increased
LAMP-2A–mediated autophagy may help to reduce levels of
mutant HTT exon 1 protein in liver cells capable of proliferation,
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Fig. 3. IKKβ is required for efficient S13 phosphorylation
of ∼350-kDa full-length mouse HTT in liver. Male R6/1
(HD) and NT WT controls, both containing the
tamoxifen-inducible Cre and floxed alleles of IKKβ,
were treated with tamoxifen or oil vehicle control at
week 10 and tissue was taken at week 16 at the
completion of the study. IKKβ normalized to loading
control ERK1/2 was significantly reduced in liver of HD
and NT mice with tamoxifen treatment over oil con-
trol in whole-cell lysate (A–C). Anti-HTT phosphoserine
13 (pS13) antibody was used to immunoprecipitate
phosphorylated full-length mouse HTT which was
then detected by Western blot with anti-total HTT
antibody. Levels of pS13-HTT were significantly re-
duced relative to total HTT with IKKβ knockout in HD
and NT controls, while levels of total HTT normalized
to ERK1/2 were not affected (A–C). Western images (A
and B) were quantitated using Scion software (C). *P <
0.05, ****P < 0.0001 values represent means ± SEM.
Statistical significance was determined by paired t test.
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but not in postmitotic neurons, keeping liver aggregate levels
lower than those observed in striatum (SI Appendix, Fig. S3).
IKKβ Knockout Increases Neuronal Degeneration and Microglial
Activation. Since striatal neurodegeneration is a hallmark of HD
(1), we asked whether overt striatal degeneration was impacted by
IKKβ knockout in R6/1 HD mice using Fluoro-Jade B staining, a
polyanionic fluorescein derivative which sensitively and specifically
binds to degenerating neurons. We quantitated Fluoro-Jade B-
positive cells in brain sections from oil vs. tamoxifen-treated HD
and NT control mice (Fig. 5A). As expected, Fluoro-Jade B-positive
striatal cells were robustly increased (∼50 fold) in oil-treated HD
mice vs. NT controls, depicting the neurodegeneration in the striatum
of R6/1 HD mice. With tamoxifen-induced IKKβ knockout, HD
mice showed an overall enhancement of the Fluoro-Jade B signal
(approximately twofold), consistent with an IKKβ knockout-mediated
increase in striatal neurodegeneration in R6/1 HD mice.
Microglia are the resident macrophages of the central nervous
system that respond to brain insults including neurodegenerative
disease (36). Microglia in striatum are increased and activated in
response to HD-associated neurodegeneration and may play both
protective and pathogenic roles in disease progression (1, 36).
Upon activation of microglia, antiionized calcium binding adaptor
molecule 1 (Iba1), a marker for microglia in mouse tissue, is up-
regulated allowing the discrimination between surveying and acti-
vated microglia (37). In both HD and NT control mice, tamoxifen-
induced IKKβ knockout resulted in significantly elevated relative
steady-state levels of striatal Iba1, demonstrating that even in the
context of healthy control striatum a reduction in neuronal IKKβ
resulted in a significant activated microglial response (Fig. 5B).
Astrocytes are star-shaped glial cells in the central nervous
system that express glial fibrillary acidic protein (GFAP), a type
of astrocyte-enriched intermediate filament protein, and respond
to all forms of injury, trauma, and infection in the brain. As-
trocyte dysfunction has previously been found to accompany and
contribute to neuronal deficits in HD model mice (38). We ex-
amined levels of GFAP by immunohistochemistry in striatum in
NT and HD mice with and without IKKβ knockout and noted
that staining of GFAP was greatly enhanced by IKKβ knockout
in NT controls to similar levels as observed in HD mice. IKKβ
knockout did not further enhance staining of GFAP beyond the
HD effect (SI Appendix, Fig. S8). The increase in GFAP-positive
astrocytes in control NT IKKβ knockout mice may reflect striatal
neuronal stress due to a loss of IKKβ function.
Discussion
We previously showed that IKKβ directly phosphorylates HTT
S13 in vitro and in cell culture and that this phosphorylation is
impaired with expansion of the HTT polyQ repeat in cells (2).
Further, it was shown that mimicking this phosphorylation in
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Fig. 5. IKKβ knockout increases neurodegeneration and microglial activa-
tion in striatum. Male R6/1 (HD) mice containing the tamoxifen-inducible Cre
and floxed alleles of IKKβ were treated with tamoxifen or oil vehicle control
for 1 wk starting at 10 wk. At the termination of the study at 16 wk, con-
secutive coronal brain sections containing striatum were stained against
Fluoro-Jade B, a neuronal death marker (A) or Iba1, a microglia marker (B).
Images (20×) show that R6/1 tamoxifen-treated mice had significant in-
creases in both Fluoro-Jade B- (A) and Iba-1– (B) positive cells in the striatum
compared with R6/1 (HD) oil-treated mice (representative images shown).
*P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 values represent means ±
SEM. Cells were counted using Bitplane’s Imaris microscopy image analysis
software and number of microglia per field of vision (FOV) graphed. Sta-
tistical comparisons of results were performed by performing one-way
ANOVA analysis followed by Bonferroni’s multiple comparison tests. n =
4 per treatment. (Scale bars, 100 μm.)
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Fig. 4. IKKβ knockout and mutant HTT exon 1 pro-
tein expression impact levels of autophagy proteins
in vivo. R6/1 (HD) or NT WT control male mice con-
taining the tamoxifen-inducible Cre and floxed al-
leles of IKKβ were treated with tamoxifen or oil
vehicle control for 1 wk starting at 10 wk to knock
out IKKβ in striatum and liver. At the termination of
the study at 16 wk, Western analysis of NT and HD
soluble fractions was used to examine levels of
autophagy proteins LC3 and LAMP-2A relative to
loading controls α-tubulin (striatum) or ERK1/2
(liver). LC3 I was detected in striatum, while LC3 I and
II were observed in liver. LC3 I was quantitated for
both tissues and was found in striatum, but not in
liver, to be significantly increased with IKKβ knock-
out or with transgene expression. LAMP-2A levels
were unchanged in striatum but were significantly
increased in HD mouse liver. Western images, shown,
were quantitated; *P < 0.05, **P < 0.01, ***P <
0.001, ****P < 0.0001 values represent means ± SEM.
Statistical significance was determined by one-way
ANOVA with Bonferroni posttesting.
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mutant HTT exon 1 protein was protective in an acute striatal
slice culture model of HD as well as in the context of full-length
mutant HTT in BACHD mice (2, 3). The current study was
initiated to evaluate whether IKKβ is a relevant kinase for HTT
S13 in vivo and to examine whether this IKKβ-mediated phos-
phorylation is consistent with a neuroprotective function in HD
progression in vivo.
We now report that IKKβ knockout in both liver and striatum
in male R6/1 mutant (HD) mice and in NT WT controls reduces
phosphorylation of WT full-length mouse HTT S13, demon-
strating that it is a relevant S13 kinase in vivo. In the current
study, IKKβ knockout in R6/1 worsened the HD behavioral
phenotype in these mice at specific time points but did not affect
NT behavior, consistent with the predicted delay in R6/1 progres-
sion from IKKβ-mediated full-length HTT S13 phosphorylation as
we observed in BACHD using phosphomimetic full-length mutant
HTT (3). Interestingly, exacerbation of phenotypes appears to be
modest and transient for the pole task, only showing significance
at the 12-wk time point but not at the 16-wk time point. We
speculate that this may be due to changes in phosphorylation of
HTT S13 at various time points, to variations in IKKβ regulation
of some autophagy genes over time, or by progressive inhibition
of autophagy by transgenic mutant HTT exon 1 protein expres-
sion with aging, but more studies will be required to clarify these
results. In the current study, we find histologically that IKKβ
knockout increases overt neuronal degeneration and microglial
activation in R6/1 striatum, suggesting that IKKβ may be es-
sential for striatal health in mice expressing mutant HTT exon
1 protein in vivo.
In 16-wk-old male R6/1 HD mice, levels of transgenic mutant
HTT exon 1 protein and aggregates were unchanged in striatum
and liver with IKKβ knockout. Using cell culture, we previously
found that WT HTT fragment clearance was increased by S13
phosphorylation and IKKβ overexpression. In contrast, mutant
HTT fragment clearance was not greatly altered upon IKKβ
overexpression and mutant HTT S13 phosphorylation was re-
duced compared with WT fragment (2). Therefore, we did not
expect transgenic mutant HTT exon 1 protein levels to be reduced
with IKKβ knockout in vivo, which proved to be the case. This is
in contrast to the reduction in aggregation we observed when
mimicking constitutive phosphorylation of HTT S13 and S16 in
full-length mutant HTT in BACHD mice where numbers of ag-
gregates were vastly reduced (3). HTT neuronal aggregate
appearance and disease onset are observed much earlier in R6/1
than in BACHD (22), which may reflect a more rapid impairment
of neuronal proteostasis and lysosomal function in the R6/1 model
due to mutant HTT exon 1 protein expression vs. the mutant full-
length HTT expression in BACHD. S13 phosphorylation in the
context of polyQ expansion is inefficient (2), and in the current
study in R6/1 we saw no evidence of transgenic mutant exon
1 protein phosphorylation in vivo, in contrast to the endogenous
full-length WT HTT which required IKKβ for efficient phos-
phorylation. In R6/1 HD and NT control striatum, levels of full-
length WT HTT increased and HTT S13 phosphorylation was
reduced with IKKβ knockout suggestive of a reduced flux of WT
full-length mouse HTT, but in liver WT full-length HTT levels
were unchanged with IKKβ knockout despite a reduction in its
S13 phosphorylation. Given that liver also has far fewer mutant
HTT exon 1 protein aggregates than striatum, proteosomal and
lysosomal protein clearance mechanisms for degradation of both
WT full-length endogenous mouse HTT and transgenic mutant
HTT exon 1 protein may be different and/or more efficient in liver
than in striatum, thus resulting in reduced mutant HTT-mediated
toxicity in liver compared with striatum. IKKβ-mediated phos-
phorylation of WT full-length mouse HTT S13 may therefore be
more important for the health of the striatum than the liver and
other tissues to maintain normal HTT function and proper pro-
teostasis. We previously showed that HTT interacts with the
mammalian Atg8 autophagy protein LC3 (39). We observed a
significant LC3 protein accumulation in striatum, but not in liver,
upon IKKβ knockout or with mutant HTT exon 1 protein ex-
pression, consistent with the hypothesis that IKKβmay regulate an
LC3-mediated type of autophagy important for striatum but not
for liver in R6/1 HD mice. In cell culture, we previously showed
that overexpression of the lysosomal membrane protein LAMP-
2A resulted in clearance of HTT exon 1 protein (2). In liver, but
not in striatum, we saw increased levels of LAMP-2A protein in
R6/1 HD mice, suggesting that activated LAMP-2A–mediated,
LC3-independent autophagy may clear mutant HTT exon 1 pro-
tein and full-length WT HTT in liver but not in striatum, reducing
aggregate numbers and contributing to liver health in HD.
Recently it was elucidated that incomplete transcription of the
mutant HTT gene results in expression of toxic mutant HTT
exon 1 protein in HD knock-in mouse models and in patients
(40, 41). Further, mutant HTT exon 1 protein expression can
activate the IKK complex (14), and IKKβ can induce expression
of several autophagy genes and up-regulate autophagy by an NF-
Kβ–independent mechanism (7, 8). Mutant HTT exon 1 protein
is an autophagic substrate and its expression has been found by
several groups to induce autophagy that activates its clearance
(32–34). Our laboratory and another have independently dem-
onstrated that at least one of HTT’s normal functions is that of a
scaffold for selective autophagy (39, 42), a function that we
propose may be induced by IKKβ-mediated phosphorylation of
HTT S13. HTT may be degraded through its own selective
autophagic scaffold function, a function that may be impaired by
expansion of the polyQ repeat, resulting in the observed accu-
mulation of mutant HTT exon 1 protein and autophagic sub-
strates in inclusions of diseased neurons (43). Therefore,
clearance of this toxic mutant exon 1 protein fragment may occur
indirectly through IKK activation and be one mechanism of
slowing HD progression in striatum. In the R6/1 HD mouse
model, however, striatal transgenic mutant exon 1 protein is
expressed at such high levels compared with those found in HD
knock-in or patient striatum that IKKβ knockout ultimately does
not impact its striatal accumulation, or that of LC3, suggesting
that autophagic flux is blocked in striatum at 16 wk in R6/1, and
at this late stage attempted activation of autophagy may be futile.
Transcriptional analysis shows that IKKβ may activate expression
of several basal autophagy genes in NT WT liver. As striatum se-
verely degenerates in HD but liver is less impacted, an increase in
autophagy gene expression in striatum may represent a compensa-
tory activation in response to the cellular stress caused by the chronic
expression of mutant HTT, a response that may not be required in
the liver. This is consistent with the hypothesis that mutant exon
1 protein clearance is more efficient in the liver and may potentially
be mediated by the observed increase in liver LAMP-2A protein
levels. Our data also suggest that early expression of IKKβ may
prolong striatal health in HD partially through the activation of
stress-induced autophagy that may be required for degradation of
mutant HTT exon 1 protein in striatum in early stages of disease.
Compensatory activation of IKKβ may therefore slow disease
progression as long as lysosomal function is intact (2, 7).
We suggest that autophagic balance regulates cell survival vs.
neurodegeneration in HD and propose the following hypothet-
ical model (Fig. 6). In premanifest HD, mutant HTT exon
1 protein is expressed due to incomplete transcription of the
mutant HTT gene (40, 41). This creates a cellular stress that
activates the IKK complex (14) to increase autophagy gene (7, 8)
and HTT expression (44) and activates phosphorylation of HTT
S13 (2), to induce autophagy important for clearance of mutant
HTT exon 1 protein (32–34) and a mitigation of the cellular
stress, allowing proteostasis to exist in a healthy balance (Fig.
6A). In manifest HD, lysosomal function and autophagy become
impaired with aging in association with polyQ expansion of HTT
and reduced HTT protein levels (31, 45), resulting in reduced
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full-length HTT phosphorylation, and mutant HTT exon 1 pro-
tein and other autophagy cargos accumulate and aggregate, or may
be expelled from the cell for prion-like propagation to neighboring
cells (46–48). The ensuing cellular stress causes a robust microglial
activation (49) and inflammatory pathway induction and accumu-
lation of IKKβ that can no longer activate autophagy (13), resulting
in cellular dysfunction and neurodegeneration (Fig. 6B). Thera-
peutics that improve lysosomal and autophagic function in young
individuals may keep mutant HTT exon 1 protein levels reduced
and slow HD progression (Fig. 6C). However, if the lysosome is
unable to degrade autophagic cargo, inhibition of autophagy may
then be neuroprotective and reduce inflammation (50–52).
The development of therapeutic approaches to treat neuro-
degenerative diseases involving an imbalance in proteostasis, in-
cluding AD, PD, ALS, HD, and other polyQ-repeat diseases, by
correcting proteostatic imbalance is an attractive avenue for ther-
apeutic development for these diseases. However, the results pre-
sented here provide a note of caution. We suggest that therapies
for these diseases may need to be developed based on whether the
patient’s lysosomal function is still intact, as early and late therapies
may be very different between the two stages. A challenge which
must be met, we believe, is an assessment of the status of the
autophagic balance of each patient at the time therapy is initiated
and the possibility that a “one-size-fits-all” therapeutic strategy may
have to be replaced by a strategy which reflects the assessment of
the autophagic balance of the patient at the time therapy is initi-
ated and a modulation of therapeutic approach in relation to
changes in the autophagic balance of the patient over time.
Materials and Methods
Experimental Animals. All experiments were carried out in strict accordance
with the Guide for the Care and Use of Laboratory Animals (53) and an
approved animal research protocol by the Institutional Animal Care and Use
Committee at the University of California, Irvine, an American Association for
Accreditation of Laboratory Animal Care-accredited institution, as previously
published in our laboratory (54). All efforts were made to minimize research
animal suffering throughout the duration of the study. A transgenic mouse
model with lox-P flanked alleles of IKKβ (23) was used for this study. Wfs1-Tg3-
CreERT2 and R6/1 mice were obtained from Jackson Laboratories (Research
Resource Identifiers IMSR_JAX: 009103 and 006471, respectively). Mice were
cross-bred to generate Wfs-CreERT2/+;IKKβflox/flox mice+/− the R6/1 transgene.
All mice were in C57BL/6 background. Mice were mix-housed under a 12-h
light/dark cycle in groups of up to five animals per cage with food and water
administered for ad libitum consumption. We performed CAG repeat sizing of
R6/1 tail snips and a subset of striatal tissue punches (Laragen). The average
transgenic CAG repeat number from R6/1 mice in this study was 132.
PCR on tail samples was used to genotype for IKKβ floxed alleles (sense
oligo: 5′-GTTCAGAGGTCCAGTCCATTATC-3′, antisense oligo: 5′-TAGCCTG-
CAAGAGACAATACG-3′). To justify experimental group and trial sizes, we
used G Power analysis based on published results (54–58) and our previous
experience and for HD mouse model studies. Based on these analyses, we
used n = 10 per group for behavioral studies and n = 4 for biochemistry Mice
were killed by pentobarbital overdose and perfused with 0.01 M PBS. Liver
was collected, striatum and cortex were dissected out of the left hemisphere,
and tissues were flash-frozen for RNA or protein isolation as described be-
low. One piece of liver and the other halves of brain were postfixed in 4%
paraformaldehyde, cryoprotected in 30% sucrose, and cut at 40 μm on a
sliding vibratome for immunohistochemistry.
Tamoxifen Protocol. To acutely delete IKKβwe used a published protocol (59).
Tamoxifen (T5648; Sigma) was suspended at a concentration of 20 mg/mL, in
a mixture of 98% sunflower oil (700011-932; VWR) and 2% ethanol. Ta-
moxifen (200 μg/g) or sunflower oil control were injected intraperitoneally
once per day for 5 d into 10-wk-old mice. Mice were dosed with tamoxifen
at a volume based on weight (i.e., 180 μL of concentration 20 μg/μL for an 18-
g mouse). Higher levels were tested and did not provide greater deletion
efficiency. During the study, 9/10 of the NT-tamoxifen females, 3/9 of the
HD-tamoxifen females, 1/12 of the NT-tamoxifen males, and 2/12 of the HD-
tamoxifen males died following tamoxifen treatment. No death was ob-
served with oil treatment in any of the groups. Because of the enhanced
lethality of tamoxifen/IKKβ knockout particularly in NT females, our analysis
was carried out exclusively with male mice.
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Fig. 6. A model for the progression of HD pathogenesis dependent on the
autophagic balance of the patient. In premanifest HD (A), mutant HTT exon
1 protein is expressed in striatum due to incomplete transcription of the mutant
HTT gene, and accumulation of mutant HTT exon 1 protein (mHTTex1p) causes a
cellular stress, which activates the IKK complex. IKKβ activates autophagy gene
expression and increases phosphorylation of HTT S13 to induce HTT’s role as an
autophagic scaffold protein. This results in autophagic clearance of mHTTex1p, ul-
timately reducing inflammation, and the cell survives. In manifest HD (B), levels of
HTT and other autophagy proteins have declined with age and the ability of the
lysosome to degrade autophagic cargos is reduced. With polyQ expansion, mutant
HTT is less well phosphorylated reducing its function as an autophagic scaffold.
mHTTex1p expressed from incomplete transcription of the mutant HTT gene ac-
cumulates and is not cleared by the lysosome, causing an up-regulation of IKK that
is unable to further activate autophagy. This results in a robust microglial activation,
massive inflammatory pathway activation, cellular dysfunction, and neuro-
degeneration. Therapies to treat HD need to be designed with the autophagic
balance of the patient in mind (C). Early therapies to activate autophagy and IKKβ
to degrade mHttex1p and reduce cellular stress may be protective as long as lyso-
somal function is still intact, but later therapies to inhibit autophagy and block IKKβ
may be useful if the aging lysosome can no longer degrade autophagic cargo.
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Behavioral Timeline and Assessment. All behavioral assessments were per-
formed as previously described (54, 60). Specifically, body weights were mea-
sured weekly at 8 to 15 wk of age. The latency to fall from the rod was
recorded over three trials then averaged and analyzed for significance. A pole
test was used to examine the ability for mice to descend a vertical pole (1 cm in
diameter, 60 cm high) at 8, 12, and 16 wk of age. Mice were habituated to the
task 1 d before testing. Mice were tested in this assay by placing them facing
down on the vertical pole and total time to descend until reaching the base
was measured. This task was performed four times with 30-s rest periods
provided between trials. Using the total time to descend from placement on
the pole as the starting point, four trials were averaged and analyzed for
statistical significance. For grip strength measurements, we used an IITC Life
Science digital force transducer instrument to measure forelimb grip force,
which gives readings in 1-g increments. Using this instrument, each mouse was
lowered toward a wire mesh by the tail and the peak force applied on a digital
display grip strength meter was measured. Mice were gently pulled back until
they released their grip from the mesh. Five consecutive trials were measured,
with the four strongest pulls averaged and analyzed for statistical significance.
Tissue Lysis, IP, Western Analysis, and Antibodies. Whole male mouse striatum
or liver tissue, taken at the end of the study at 16 wk, was dounced 20 times on
ice inmodified RIPAbuffer (50mMTris·HCl, pH7.4, 1%Nonidet P-40, 0.25%Na-
doxycholate, 150 mM NaCl, and 1 mM EDTA) containing a complete protease/
phosphatase-inhibitor pellet (Thermo), 1 μg/mL leupeptin and aprotenin,
phosphatase inhibitors 2 and 3 (Sigma-Aldrich), and 1 mM PMSF. Homogenate
lysates were centrifuged at 16.1 × g for 15 min at 4 °C. Protein concentration
was determined on the supernatant by Bradford assay. IP was done as pre-
viously described (3), summarized as follows: 500 μg of supernatant was
incubated ± 1 μL pS13 antibody for 1 h on ice in a total volume of 30 μL. Thirty
microliters of Protein-G Dynabeads (Invitrogen) were preequilibrated and
washed in 100 mM phosphate buffer (pH 5.0), and the buffer was removed
using a magnetic rack. The beads were resuspended in the supernatant/anti-
body mixture and rocked for 45 min at 4 °C. They were then washed using a
magnetic rack three times in 200 μL of 100 mM phosphate buffer (pH 5.0). The
beads were resuspended in 25 μL of loading buffer (Invitrogen), incubated at
70° C for 10 min, and run on 3 to 8% Tris-acetate gels (Invitrogen). These gels
were blotted to PVDF (Millipore), blocked with SuperBlock BlockingBuffer
(ThermoScientific), and subjected to Western analysis using PICO reagent
(Thermo) exposed to film for images. Protein quantification was performed by
Scion Image analysis software. Band densities from whole-cell lysates were
normalized to α-tubulin for striatum and ERK1/2 for liver. Antibodies used
were anti-HTT phosphoserine 13 pS13 (2) 1:1,000, anti-HTT VB3130 (N17 epitope)
to detect full-length ∼350 kDa mouse WT HTT levels (Viva Bioscience)
1:1,000, anti-α-tubulin (Sigma-Aldrich) 1:5,000, anti-ERK1/2 (Cell Signaling)
1:1,000, and anti-IKKβ (Abcam 10AG2) 1:500. Anti-LC3 antibody (MBL) was
used at 1:1,000 and anti-LAMP-2A antibody (Zymed) at 1:500. Whole-cell
supernatant was run at concentrations 30 μg per lane for striatum and 50
μg per lane for liver and subjected to Western analysis.
Analysis of Transgenic Mutant HTT Exon 1 Protein Levels by Western Analysis.
ForWestern analysis, striatal tissue was the same as that used for the above IP
studies. Liver tissue was dounced 30 times in lysis buffer (10 mM Tris, pH 7.4,
1% Triton X-100, 150 mM NaCl, 10% glycerol, 20 mM N-ethylmaleimide,
0.2 mM phenylmethylsulfonyl fluoride, 1 mM Na3VO4, 1 μg/mL leupeptin,
1 μg/mL aprotinin, and 20 mM NaF), allowed to rest on ice for 1 h, then
centrifuged at 15,000 × g at 4 °C for 20 min and the resulting supernatant
was quantitated by Lowry assay. Thirty micrograms per lane of striatal and
liver soluble whole-cell extracts were run on 4 to 12% Bis-Tris MidiGels (Invi-
trogen) using Mops running buffer and transferred onto 0.45-μm nitrocellu-
lose membranes. We detected transgenic human mutant HTT exon 1 protein
smears in the soluble fraction by Western analysis using anti-human HTT
MAB5492 (Millipore) at 1:1,000, which does not recognize endogenous mouse
HTT, quantitated using Scion Image analysis software, and performed statis-
tical analyses with GraphPad Prism 6, version 6.01. This liver tissue lysis protocol
and gel system was also used to compare levels of IKKβ in oil-treated R6/1 (HD)
vs. NT animals using anti-IKKβ (10AG2; Abcam) 1:500. Loading controls for
striatum and liver were measured using anti–α-tubulin (Sigma-Aldrich) at
1:5,000 and anti-ERK1/2 (Cell Signaling) at 1:1,000, respectively.
Quantitation of Mutant HTT Aggregates in Striatum. Half-brain coronal sec-
tions, 40 μm each, four sections per 16-wk-old male mouse, were used for
quantitation. Sections were picked from bregma 1.34, every 12 sections, to
bregma −0.1, from male R6/1 mice containing the Cre and floxed alleles of
IKKβ (HD) and treated with tamoxifin or oil vehicle control, four mice per
treatment group. Fluorescent immunolabeling was done with anti-HTT
clone mEM48 (MAB5374; Millipore) to label transgenic human mutant HTT
exon 1 protein aggregates and TO-PRO-3 Iodide stain (T3605; Thermo Fisher
Scientific) to label nuclei. Images were captured using Leica confocal mi-
croscope (DM2500) and Leica camera TCS SPE (Leica Microsystems Inc.). Im-
ages were taken at 40×, with z-volume set at 25 to 30 μm at 1 μm per step.
Three striatal areas, upper, middle and lower, were imaged with consistent
settings for laser intensity, exposure time, and gain through all images.
Imaris x64 quantitation software (Bitplane Scientific Software) was used to
evaluate the number of aggregates in each area normalized to the number
of nuclei, calculated as the percent of cells expressing aggregates.
Quantitation of Mutant HTT Aggregates in Liver. Paraffin-embedded liver
sections, 40 μm per section, from male 16-wk-old R6/1 mice containing the
Cre and floxed alleles of IKKβ (HD), treated with tamoxifin (n = 5) or oil
vehicle control (n = 4), were used. One section per mouse was analyzed.
Fluorescent aggregate immunolabeling was done with anti-HTT MW8
(AB528297; Developmental Studies Hybridoma Bank) (recommendation
from Jeffrey Carroll for liver HTT, Western Washington University, Bellingham,
WA) and TO-PRO-3 Iodide stain (T3605; Thermo Fisher Scientific) was used to
label nuclei. Images were captured using Leica confocal microscope (DM2500)
and Leica camera TCS SPE (Leica Microsystems Inc.). All images were taken at
20×, two areas per section, with consistent settings for laser intensity, expo-
sure time, and gain through all images. In each area, the number of aggre-
gates was counted by eye without normalization, as aggregate numbers were
very low and visible per field.
Quantitation of Liver Lipid Droplets. Bodipy 493/503 (D3922; Thermo Fisher)
was used to stain neutral lipids in paraformaldehyde-fixed 40-μm male liver
slices. Bodipy 493/503 was stored as stock of 1 mg/mL in DMSO. Three PBS
washes of tissue were followed by staining with bodipy diluted to 10 μg/mL
in PBS for 30 min at room temperature. This was followed by 1-min in-
cubation in 1:5,000 Hoechst reagent to stain nuclei, followed by three PBS
washes and mounting of tissue using fluoromount. Z-stack images were
taken using a confocal microscope and surface area and volume of lipids
determined using Imaris x64 quantitation software (Bitplane Scientific
Software). The analysis was done on 16-wk-old male mouse liver using two
images per liver section, three sections per animal, four animals per group.
Quantification was performed using Imaris image software to calculate
surface area of lipid droplets and cell number for normalization. Cell num-
ber was quantified using DAPI staining.
Analysis of Microglia in Striatum. For immunohistochemical assessments,
40-μm sections of postfixed half-brains from four 16-wk-old male mice per
treatment group were processed for immunohistochemistry and imaged via
confocal microscopy. The following primary antibody was used: anti-Iba1
(27030; Wako Pure Chemicals Industries). Alexa fluorescent-conjugated
secondary antibody was used (A21428; Thermo Fisher Scientific). Coronally
sectioned stained tissue was processed and mounted on slides with
Fluoromount-G (SouthernBiotech). Images were captured using Leica con-
focal microscope (DM2500) and Leica camera TCS SPE (Leica Microsystems
Inc.). Five comparable representative images per treatment group were
taken at 10×, 20×, and 63× z stack, with consistent settings for laser in-
tensity, exposure time and gain through all images. Automatic analyses and
cell quantitation from acquired images was processed using Imaris
x64 quantitation software (Bitplane Scientific Software).
Fluoro-Jade B Analysis of Neurodegeneration in Striatum. Analysis was done
using four male postfixed half-brains for each treatment group, with five
40-μm representative sections prepared from each. Stack images (20×) were
obtained using confocal microscopy at comparable sections for each animal.
Images were captured using Leica confocal microscope (DM2500) and Leica
camera TCS SPE (Leica Microsystems Inc.). Striatal sections were mounted on
Shandon Polysine slides (Thermo Scientific), allowed to dry completely, and
immersed in a series of washes: (i) 3 min in 80% ethanol, (ii) 2 min in 70%
ethanol, (iii) 2 min in a 1:200 dilution of acetic acid to MilliQ water, (iv)
10 min gently rocking in 0.06% KMnO4 solution, (v) 2 min in a 1:200 dilution
of acetic acid to MilliQ water, (vi) 15 min gently rocking in 0.0004% Fluoro-
Jade B (AG310; Millipore Sigma) solution, and (vii) three sequential 1-min
rinses in a 1:200 dilution of acetic acid to MilliQ water. Slides were allowed
to dry, immersed in three sequential 1-min washes with 100% xylene,
allowed to dry again, and coverslipped with DPX mounting medium (Elec-
tron Microscopy Sciences).
GFAP Free-Floating Immunohistochemistry Protocol. Sections were incubated
in 1% hydrogen peroxide in Tris-buffered saline (TBS; 0.05 M Tris, 145 mM
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NaCl, pH 7.6) for 30 min followed by three washes in TBS. After incubation
in 15% (vol/vol) normal goat serum (S-1000; Vector Laboratories) in TBST
(TBS with 0.3% Triton X-100) for 30 min, sections were then incubated in
GFAP primary antibody (1:400 dilution, Z033429-2; Dako) in 10% (vol/vol)
normal goat serum in TBST overnight. After three washes in TBS, sections
were incubated with biotinylated secondary antibody (1:1,000 dilution,
BA-1000; Vector Laboratories) in 10% (vol/vol) normal goat serum in TBST
for 2 h. Sections were then washed three times in TBS and stained using
Vectastain Elite ABC HRP Kit (PK-6101; Vector Laboratories) (1:1,000 di-
lution reagent A, 1:1,000 dilution reagent B) for 2 h. After two more
washes in TBS, sections were then stained using DAB Peroxidase Substrate
Kit (SK-4100; Vector Laboratories). After 1.5-min incubation in DAB sub-
strate solution, sections were washes two times in ice-cold TBS, mounted
on gelatin-coated slides, and coverslipped using Permount mounting
medium (SP15-100; Fisher Scientific). Sections were viewed on an Olympus
BX53 microscope, images with identical capture settings were acquired
using a QImaging QIClick CCD camera and Q-Capture Pro-7 software, and
brightness/contrast adjustments were made in parallel (via adjustment
layer) in Photoshop.
RNA Extraction and qPCR. Striatal and liver tissues were homogenized in
TRIzol (Invitrogen) and total RNA was isolated using an RNEasy Mini kit
(QIAGEN) with supplemental DNase treatment to remove residual DNA.
Reverse transcription was performed using oligo dT primer sets and 1 μg
total RNA using SuperScript III First-Strand Synthesis System (Invitrogen)
as previously described (54). The qPCR was performed as previously de-
scribed (61) and CT values for each gene of interest (GOI) were normalized
against RPLPO to calculate dCT values. For statistical analysis ddCT values
were used in a two-way ANOVA for each GOI. Post hoc analyses using
Tukey’s honestly significant difference test with Bonferroni correction
were used to test statistical significance between each group interaction
contrast. Adjusted P values are reported. While the Wfs1 promoter can
also affect cortex and cerebellum, we did not observe major qPCR
changes in IKKβ expression in male cortex or cerebellum in either HD or
NT mice with tamoxifen treatment. We therefore did not further evaluate
these tissues.
Primer sequences (5′–3′) used were as follows:
HTT.
Forward sequence: GCAGGGAAAGAGCTTGAGACAC
Reverse sequence: CCTCATTCTCCTTGTGGCACTG
Beclin1.
Forward sequence: CAGCCTCTGAAACTGGACACGA
Reverse sequence: CTCTCCTGAGTTAGCCTCTTCC
Atg5.
Forward sequence: CTTGCATCAAGTTCAGCTCTTCC
Reverse sequence: AAGTGAGCCTCAACCGCATCCT
Atg7.
Forward sequence: CCTGTGAGCTTGGATCAAAGGC
Reverse sequence: GAGCAAGGAGACCAGAACAGTG
LC3A.
Forward sequence: CTGCCTGTCCTGGATAAGACCA
Reverse sequence: CTGGTTGACCAGCAGGAAGAAG
GABARAPL1.
Forward sequence: GTGGAGAAGGCTCCTAAAGCCA
Reverse sequence: AGGTCTCAGGTGGATCCTCTTC
p62/SQSTM1.
Forward sequence: GCTCTTCGGAAGTCAGCAAACC
Reverse sequence: GCAGTTTCCCGACTCCATCTGT
Atg16L.
Forward sequence: GGACACTCATCCTGCTTCTGGT
Reverse sequence: GCTTCCCAAAGTTTCACCCTGC
mAtg13.
Forward sequence: AGAGACTGGTGATGCACATGCC
Reverse sequence: CCGTCCTTCACTGCTGTTAGAC
IKKβ.
Forward sequence: GCAGACTGACATTGTGGACCTG
Reverse sequence: ATCTCCTGGCTGTCACCTTCTG
RPL18A.
Forward sequence: GAAGGTGGAAGAGATTGCAGCTG
Reverse sequence: TCTTGGTGGTGAAGCGTGGCTT
Atp5b.
Forward sequence: CTCTGACTGGTTTGACCGTTGC
Reverse sequence: TGGTAGCCTACAGCAGAAGGGA
Atg9A.
Forward sequence: GTTAGCTGTGGAACACGTCCTC
Reverse sequence: GCAAGAATCACTCGGAGCAGCT
Atg14.
Forward sequence: CAGCAAGCAGAAACTGACACGC
Reverse sequence: GACCAAGTGCATCAGGTTCCTG
BNIP3.
Forward sequence: GCTCCAAGAGTTCTCACTGTGAC
Reverse sequence: GTTTTTCTCGCCAAAGCTGTGGC
NIX (BNIP3L).
Forward sequence: GCATGAGGAAGAGTGGAGCCAT
Reverse sequence: AAGGTGTGCTCAGTCGTTTTCCA
FIP200 (RB1CC1).
Forward sequence: GGAATCTCTGGTCAGGAAGTGC
Reverse sequence: GTCCAAGGCATACAGCCGATCT
LAMP-2A.
Forward sequence: AGGTGCTTTCTGTGTCTAGAGCGT
Reverse sequence: AGAATAAGTACTCCTCCCAGAGCTGC
LAMP-2B.
Forward sequence: ATGTGCTGCTGACTCTGACCTCAA
Reverse sequence: TGGAAGCACGAGACTGGCTTGATT
LAMP-2C.
Forward sequence: ACCACCAATCTAAGAGCAGGACT
Reverse sequence: GGTGCTGGTCTTTCAGGCTTGATT
TFEB.
Forward sequence: CCACCCCAGCCATCAACAC
Reverse sequence: CAGACAGATACTCCCGAACCTT
TG2.
Forward sequence: GAAGGAACACGGCTGTCAGCAA
Reverse sequence: GATGAGCAGGTTGCTGTTCCTGG
Atg10.
Forward sequence: GAGACCTTGACACCACATGCCA
Reverse sequence: GCAGGTCTCGTCACTTCAGAATC
RPLPO.
Forward sequence: TGGTCATCCAGCAGGTGTTCGA
Reverse sequence: ACAGACACTGGCAACATTGCGG
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